Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
Type:
Grant
Filed:
November 13, 2008
Date of Patent:
October 5, 2010
Assignee:
Genentech, Inc.
Inventors:
Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, William I. Wood
Abstract: A method for reducing leaching of protein A during protein A affinity chromatography is described which involves reducing temperature or pH of, or by adding one or more protease inhibitors to, a composition that is subjected to protein A affinity chromatography.
Type:
Grant
Filed:
November 12, 2008
Date of Patent:
October 5, 2010
Assignee:
Genentech, Inc.
Inventors:
Robert L. Fahrner, Amy Laverdiere, Paul J. McDonald, Rhona M. O'Leary
Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
Type:
Grant
Filed:
September 8, 2004
Date of Patent:
September 28, 2010
Assignee:
Genentech, Inc.
Inventors:
Belinda Cairns, Ruihuan Chen, Gretchen Frantz, Kenneth J. Hillan, Hartmut Koeppen, Heidi S. Phillips, Paul Polakis, Susan D. Spencer, Victoria Smith, P. Mickey Williams, Thomas D. Wu, Zemin Zhang, Chie Sakanaka, Anan Chuntharapai, Chae Janeka Reed
Abstract: A formulation comprising a therapeutically effective amount of an antibody, optionally, not subjected to prior lyophilization, a buffer maintaining the pH in the range from about 4.5 to about 6.5, and an optional surfactant is described, along with uses for such a formulation.
Abstract: Methods for the treatment of cancer with combination therapies that include anti-VEGF antibodies are provided. Methods for diagnosing resistant tumors are also provided.
Abstract: The present invention provides novel polypeptides, antibodies, antagonists, agonists, potentiators, nucleic acid molecules, compositions and methods relating to the STOP-1 polypeptide that are useful for treating and preventing diseases and for medical diagnosis and research. The present invention also provides consensus sequences and specific sequences for antibodies that specifically bind to STOP-1 that are useful in the methods described herein.
Type:
Grant
Filed:
April 16, 2004
Date of Patent:
September 21, 2010
Assignee:
Genentech, Inc.
Inventors:
Heidi Ackerly, Avi Ashkenazi, David Eberhard, Gretchen Frantz, Dorothy French, Germaine G. Fuh, Jo-Anne S. Hongo, Chingwei V. Lee, Scot A. Masters, Helga A. Raab, Evgeny Varfolomeev, Beni B. Wolf, Robert Maurice Pitti, Liliana Soroceanu
Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO1105, PRO1279 or PRO1783 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.
Type:
Application
Filed:
October 1, 2007
Publication date:
September 16, 2010
Applicants:
GENENTECH, INC., LEXICON PHARMACEUTICALS, INC.
Inventors:
Mark Dominic Borromeo, Jaime-Jo Cunningham, Frederick Desauvage, Ellen Filvaroff, Mark Alan Klamer, Laurie Jeanette Minze, Bobby Joe Payne, Carolina Rangel, Zheng-Zheng Shi, Peter Vogel
Abstract: Methods for treating multiple sclerosis (MS) with a CD20 antibody using special dosing regimens and protocols are described. Articles of manufacture for use in such methods are also described.
Abstract: The invention relates to the identification and isolation of novel DNAs encoding the human Toll proteins PRO285, PRO286, and PRO358, and to methods and means for the recombinant production of these proteins. The invention also concerns antibodies specifically binding the PRO285, or PRO286, or PRO358 Toll protein.
Type:
Application
Filed:
March 3, 2010
Publication date:
September 16, 2010
Applicant:
GENENTECH, INC.
Inventors:
Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Melanie R. Mark, Ruey-Bing Yang
Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
Type:
Grant
Filed:
March 18, 2008
Date of Patent:
September 14, 2010
Assignee:
Genentech, Inc.
Inventors:
Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, William I. Wood
Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.
Type:
Application
Filed:
October 8, 2009
Publication date:
September 9, 2010
Applicant:
Genentech, Inc.
Inventors:
Gwendolyn Fyfe, Eric Holmgren, Robert D. Mass, William Novotny
Abstract: The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc region thereof.
Abstract: The invention provides anti-Unc5B antibodies, compositions and kits comprising the antibodies and methods of making and using the antibodies. The present invention also relates to use of anti-Unc5B antibodies to modulate angiogenesis and to treat or prevent disorders associated with abnormal angiogenesis.
Type:
Application
Filed:
November 19, 2009
Publication date:
September 2, 2010
Applicant:
Genentech, Inc.
Inventors:
Alexander W. Koch, Ryan J. Watts, Yan Wu, Anil D. Bagri
Abstract: NTNR?, NTNR? extracellular domain (ECD), NTNR? variants, chimeric NTNR? (e.g., NTNR? immunoadhesion), and antibodies which bind thereto (including agonist and neutralizing antibodies) are disclosed. Various uses for these molecules are described, including methods to modulate cell activity and survival by response to NTNR?-ligands, for example NTN, by providing NTNR? to the cell.
Type:
Grant
Filed:
August 22, 2006
Date of Patent:
August 31, 2010
Assignee:
Genentech, Inc.
Inventors:
Robert D. Klein, Arnon Rosenthal, Mary A. Hynes
Abstract: The invention provides polypeptides comprising a variant heavy chain variable framework domain (VFR). In some embodiments, the amino acids defining the VFR form a loop of an antigen binding pocket. In an embodiment, the polypeptide is a variable domain of a monobody and has a variant VFR. The polypeptide may optionally comprise one or more complementary determining regions (CDRs) of antibody variable domains. In an embodiment, the polypeptide is a variable domain of a monobody and has a variant VFR and one or more variant CDRs. Libraries of polypeptides that include a plurality of different antibody variable domains generated by creating diversity in a VFR, and optionally, one or more CDRs are provided and may be used as a source for identifying novel antigen binding polypeptides that can be used therapeutically or as reagents. The invention also provides fusion polypeptides, compositions, and methods for generating and using the polypeptides and libraries.
Abstract: The invention provides diagnostic, prognostic, and therapeutic uses for detecting COP1 overexpression in a variety of cancers. The methods and uses can further include detecting p53 expression. The invention also provides reagents and kits for use in screening for test compounds that interfere with COP1 and p53 binding.
Type:
Grant
Filed:
April 10, 2007
Date of Patent:
August 31, 2010
Assignee:
Genentech, Inc.
Inventors:
David Dornan, Dorothy French, Vishva Dixit